Literature DB >> 18025205

Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.

Jean-René Pallandre1, Emilie Brillard, Gilles Créhange, Amandine Radlovic, Jean-Paul Remy-Martin, Philippe Saas, Pierre-Simon Rohrlich, Xavier Pivot, Xiang Ling, Pierre Tiberghien, Christophe Borg.   

Abstract

Immunological tolerance is maintained by specialized subsets of T cells including CD4(+)CD25(+)FOXP3(+) regulatory cells (Treg). Previous studies established that Treg thymic differentiation or peripheral conversion depend on CD28 and Lck signaling. Moreover, foxp3 gene transfer in murine CD4(+)CD25(-) T lymphocytes results in the acquisition of suppressive functions. However, molecular pathways leading to FOXP3 expression remain to be described. In this study, we investigated the molecular events driving FOXP3 expression. We demonstrated that CD28 activation in CD4(+)CD25(-) T lymphocytes leads to STAT3 Tyr(705) phosphorylation in an Lck-dependent manner. STAT3 neutralization during naive peripheral CD4(+)CD25(-) T cell conversion into Treg through costimulation with TCR/CD28 and TGF-beta1, decreased FOXP3 expression, prevented the acquisition of suppressive functions and restored the ability of the converted lymphocytes to produce IL-2 and IFN-gamma. Furthermore, we observed that STAT3 ablation using small interfering RNA strategies inhibited FOXP3 expression and suppressive functions among naturally differentiated CD4(+)CD25(+) T lymphocytes, suggesting a direct role of STAT3 in Treg phenotype and function maintenance. CD4(+)CD25(+) T lymphocytes transduced with specific STAT3 small interfering RNA were devoid of suppressive functions and failed to control the occurrence of acute graft-vs-host disease. Finally, STAT3 inhibition in CD4(+) lymphocytes enhanced the anti-tumor immunity conferred by a lymphocyte adoptive transfer. In summary, our findings determine that STAT3 is critical in the molecular pathway required for FOXP3 expression. STAT3 modulation should be taken into account when assessing how regulatory T cells contribute to inflammatory diseases and tumor immunosurveillance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025205     DOI: 10.4049/jimmunol.179.11.7593

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

Review 1.  Regulatory T cell migration during an immune response.

Authors:  Yaozhong Ding; Jiangnan Xu; Jonathan S Bromberg
Journal:  Trends Immunol       Date:  2012-02-02       Impact factor: 16.687

2.  p38 Mitogen-activated protein kinase/signal transducer and activator of transcription-3 pathway signaling regulates expression of inhibitory molecules in T cells activated by HIV-1-exposed dendritic cells.

Authors:  Karlhans Fru Che; Esaki Muthu Shankar; Sundaram Muthu; Sasan Zandi; Mikael Sigvardsson; Jorma Hinkula; Davorka Messmer; Marie Larsson
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

3.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

4.  Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer.

Authors:  Xiaowei Chen; Yoshihiro Takemoto; Huan Deng; Moritz Middelhoff; Richard A Friedman; Timothy H Chu; Michael J Churchill; Yan Ma; Karan K Nagar; Yagnesh H Tailor; Siddhartha Mukherjee; Timothy C Wang
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

Review 5.  Tregs and infections: on the potential value of modifying their function.

Authors:  Sharvan Sehrawat; Barry T Rouse
Journal:  J Leukoc Biol       Date:  2011-09-13       Impact factor: 4.962

6.  Growth hormone prevents the development of autoimmune diabetes.

Authors:  Ricardo Villares; Dimitri Kakabadse; Yasmina Juarranz; Rosa P Gomariz; Carlos Martínez-A; Mario Mellado
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 7.  Engineering better immunotherapies via RNA interference.

Authors:  Mouldy Sioud
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.

Authors:  Nicolas Larmonier; Nona Janikashvili; Collin James LaCasse; Claire Billerey Larmonier; Jessica Cantrell; Elaine Situ; Tamara Lundeen; Bernard Bonnotte; Emmanuel Katsanis
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

9.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.

Authors:  Marcin Kortylewski; Hong Xin; Maciej Kujawski; Heehyoung Lee; Yong Liu; Timothy Harris; Charles Drake; Drew Pardoll; Hua Yu
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

10.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.